Overview

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help doctors learn how pemetrexed disodium works in the body and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying the side effects and how well pemetrexed disodium works in treating patients with leptomeningeal metastases.
Phase:
Early Phase 1
Details
Lead Sponsor:
Northwestern University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Pemetrexed